Crinetics Pharmaceuticals(NASDAQ) CRNX

Crinetics makes oral pills for rare hormone diseases.

Their medicine helps people manage growth hormone issues.

These treatments replace the need for painful injections.

Treating Rare Hormone Disorders

• PALSONIFY: Oral treatment for adults with acromegaly, a condition where the body produces too much growth hormone; accounts for 96% of revenue.
• Atumelnant: Investigational drug candidate in Phase 2 and 3 clinical trials for adrenal gland disorders.
• CRN09682: Discovery-stage program designed to treat certain types of solid tumors that express specific receptors.
• Licensing Agreements: Revenue generated from sharing data and intellectual property with international partners; accounts for 4% of revenue.

Recent Strategic Moves

• Launched PALSONIFY in the United States in late 2025 following approval from the Food and Drug Administration.
• Received approval from the European Commission in April 2026 to treat adults with acromegaly across the European Union.
• Partnered with Sanwa Kagaku Kenkyusho Co., Ltd as they submitted a new drug application for acromegaly treatment in Japan.
• Raised $380 million in net proceeds through a public stock offering completed in January 2026.
• Licensed radiotherapeutic technology to Radionetics Oncology, Inc. in exchange for a significant equity stake and future milestones.

Patient Focused Drug Design

Crinetics specializes in creating small molecules that target G-protein coupled receptors, which are proteins that help cells communicate and regulate hormones. This approach allows the company to develop oral pills that offer a simpler alternative to the long-acting injections typically used for rare endocrine diseases.

Financial Trajectory

• Total revenue reached $10.7 million in Q1 2026, up from $361,000 in Q1 2025.
• Net loss deepened to $127.8 million in Q1 2026, worsening 32.1% year-over-year.
• Operating cash flow was negative $124.7 million in Q1 2026, worsening 41% from the previous year.
• Cash and investment securities totaled $1.3 billion as of March 31, 2026.

Bottom Line

Crinetics has successfully transitioned from a research-focused clinical stage company to a commercial organization with its first approved drug. Its robust cash position and expanding pipeline support its efforts to modernize the treatment of rare endocrine disorders and related tumors.